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Nanomedicine for the Treatment of Non-Hodgkin Lymphoma
Tanvi Gandhi, B.Pharm
Abstract: Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic
malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually. For
decades, chemotherapy was the standard treatment of care, but since the discovery in 1997, monoclonal antibodies are increasingly
used as an alternate form of therapy. Nonetheless, almost 20,000 Americans succumb to NHL annually, which highlights the
translational gap between preclinical research and the market. Although a lot of progress has been made in therapy options by
immunotherapy and combination chemotherapy, the ingenuity of nanomedicine may bridge the translational difficulties while serving
as a novel form of therapy capable of eradicating solid tumors. The versatility of nanoparticles allows for personalized approach to NHL,
as opposed to generalized medicine, since the subtypes of lymphoma are pathologically very different from one another.

EMERGENCE OF NANOMEDICINE
Non-Hodgkin lymphoma (NHL) affects many Americans
annually, with a growth of over 5,000 diagnoses in the U.S.
annually, totaling approximately 75,000 diagnoses in 2018.1,2
Commonly used treatment options for oncological diseases
comprise of chemotherapy, radiation, and stem cell
transplants.2,3 The most common off-target complication for all
these current therapy alternatives is the death of non-cancerous
cells due to non-specificity of the treatment used. The
translational laboratory-to-market pathway is facing a major
road block due to this adverse effect which in turn undermines
the efficacy of the original treatment.3 This provides opportunity
for better suited carriers or a formulation system which will show
higher efficacy than nonspecific binding of cells.4 In this regard,
since the discovery in the 1980s, nanoparticles have been rapidly
conquering the translational medicine sector. There is a growing
interest in nanomedicine, which is the application of
nanoparticles for therapeutic purposes.4 Nanoparticles are not
only making it possible to use newly discovered molecular
entities in a more suitable formulation but are also bridging the
time gap between laboratory discovery and patient use.
Since its introduction in 1974, nanotechnology has rapidly been
researched, allowing its movement into clinical trials.3 Ever since
the first FDA approval for Doxil®, an increasing number of phase
II and phase III clinical trials are now focusing on nanomedicine.4
The major advantage of using nanoparticles is the versatility in
size, solubility, and drug loading.5 Based on the desired
targeting and candidate drug properties, an ideal system can be
selected as a carrier. Sizes for nanoparticles range from 50
nanometers to 200 nanometers, where the smaller size helps to
improve the pharmacokinetic profile of the drug by ensuring it
stays in the system longer. Drug loading can be improved based
on hydrophilicity of the drug. More hydrophobic drugs should
be loaded into nanoemulsions or liposomes while hydrophilic
drugs are better suited with micelles.5

membrane fusion for cell internalization.6,7 Although
endocytosis is the more prevalent of the two methods, there are
still issues with insufficient drug release due to endosomal
escape or degradation by lysosomes.8 Cell membrane fusion is
a mechanism proposed to be used particularly by liposomes,
wherein the similarity in phospholipid composition of cell membrane and liposomal membrane causes the membranes to fuse.8
Newer targeting mechanisms involve the use of stimuliresponse release, which may be based on temperature, pH, light,
or enzymes.6,7
Due to the advancement and increasing success of
nanomedicine in cancer, scientists are applying the same
principles of nanoparticles to the research in the fields of other
chronic illnesses like diabetes and cardiovascular disease.9
Engineered nanoparticles have unlocked new avenues by not
only providing sophisticated treatment options but also giving
us access to early diagnosis of various cancers. The diagnostic
capabilities combined with the therapeutic power has enabled
nanoparticles to be designed with target specificity, thereby
reducing the off-target adverse effects.9 Table 1 highlights the
nanoparticulate formulations currently approved by the FDA on
the market.

CHALLENGES IN CLINICAL TRANSITION
Clinical translation of nanomedicine is not only expensive but
also a very time-intensive process. From a formulation aspect, it
is harder to manufacture nanoparticles with the same
reproducibility and quality as the traditional forms of medicine,
such as tablets, injectables, and suspensions.9,10 There are several
factors, including cancer pathophysiology, manufacturing scaleup, toxicology profile, and biocompatibility, which pose as
market barriers, irrespective of the increasing number of preclinical research articles being published.11,12

Where most formulations struggle with delivery of the drug
within the cancer cells due to the barrier of penetrating the cell
membranes, nanoparticles use the process of endocytosis or cell
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Drug

Formulation

Indication(s)

Manufacturer

FDA approval
date

Oncaspar

PEG-asparaginase

ALL

Sigma-Tau
Pharmaceuticals

1994

Doxil/Caelyx

Pegylated liposomal
doxorubicin

Ovarian cancer, multiple myeloma and
AIDs-related Kaposi’s sarcoma

Janssen-Cilag
International

1995

DuanoXome

Liposomal daunorubicin

Advanced HIV-related Kaposi’s sarcoma

Galen US

1996

DepoCyt

Liposomal cytarabine

Lymphomtous meningitis

Pacira
Pharmaceuticals

1999

Myocet

Liposomal doxorubicin

Metastatic breast cancer

Teva
Pharmaceuticals

2000

Abraxane

Albumin-bound
paclitaxel nanospheres

Metastatic pancreatic cancer and other
related cancers

Celgene

2005

Genexol-PM

Pacitaxel loaded
polymeric micelle

Metastatic breast cancer and NSCLC

Samyang

2007 (in Korea)

Marqibo

Liposomal vincristine
sulphate

Philadelphia chromosome-negative
lymphoblastic leukemia

Talon therapeutics

2012

TABLE 1: FDA approved nanoparticle formulations for cancer (NSCLC: Non-small cell lung cancer; ALL: Acute lymphoblastic leukemia)8
TYPES OF NANOCARRIERS
Although most of the nanoparticle products on the market
comprise of liposomes as the nanocarrier, polymers and some
metals are now being used in the formulation as well.13,14 The
choice of the carrier is crucial to efficacy of the formulation and
depends largely on the therapeutic material to be encapsulated.
For instance, delivery of siRNA demands high endosomal
escape, hence a carrier with that ability must be designed.13
Choice of vehicle has an impact on the ADME profile of the final
product and each carrier has its own merits and pitfalls.
Nanoparticles may be broadly classified as rigid, such as
polymeric and inorganic nanoparticles, or non-rigid, such as
liposome, micelle and solid lipid nanoparticle. Another form of
classification divides them into organic nanoparticles, including
micelle, liposome, nanogel and dendrimer, and inorganic
nanoparticles, including SPIONs, gold nanoparticles, quantum
dot nanoparticles and paramagnetic lanthanide ions.13

CONCLUSION AND FUTURE SCOPE
Although over 5% of newly diagnosed cancers are categorized
as NHL, not many chemotherapeutic regimens are approved by
the FDA to improve the patient survival and quality of life.13
Immunotherapy has greatly improved the NHL outcomes, but
the prognosis of NHL remains poor as compared to other
cancers.15 The introduction of nanotherapeutics might
revolutionize the NHL market by providing better tolerance for
the current drugs while obtaining the desired cytotoxicity for
cancer cells. Currently, five different types of nanoparticles are
being investigated in clinical trials.15

Moving forward, identifying and overcoming the crucial
challenges will help NHL-directed nanomedicine to evolve and
reach the market. Some of these challenges include targeting
and selectivity, making it able to move beyond the EPR
(enhanced permeability and retention) effect.16 Nanoparticles
can be engineered to target a ligand as well as encapsulate
molecular targeting agents. In addition to delivering
encapsulated drugs, nanoparticles can be used to effectively
deliver nucleic acids, antibodies and other genetic materials.16
Another challenge in developing anti-lymphoma nanotherapeutics is the translation from lab to market. Very few of
the formulations which work in vivo translate those results in
humans since the physiologies of the two species are different.16
For clinical trials, the enrolment is a lengthy process and most of
the subjects are patients who have failed to respond to the
standard of care treatments. Taking into consideration the outcome of this disease in the absence of medicine, blinding of
clinical trials would be unethical and could lead to a further
reduction in the trial participation. More recently, canine clinical
trials are being conducted with dogs which naturally contracted
NHL.16 Since disease progression is faster in dogs, the time for
clinical trials is also relatively reduced.15
In the future, nanomedicine synthesized using lipids, polymers
and chemotherapeutic drugs will play an important role in the
treatment regimen for NHL. Coupling the recent and exciting
discovery of CRISPR-Cas9 with nanoparticles would serve as a
powerful permanent genetic manipulation tool allowing
mutations and correction of translocations.16,17 Since the vast
majority of NHL arises due to genetic aberrations, such as mantle
cell lymphoma, the disease could be a perfect target for this new
technology.17 This system could also have advantages over some
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of the other commonly used nucleic acids, including siRNA and
DNA.17
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